TLPH · XBRL financial data
Talphera financial statements, every fiscal year
The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (TLPH's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cost of goods and services sold | 6,032 | 3,753 | 2,591 | — | — | — |
| Research and development | 4,017 | 4,095 | 5,193 | 5,546 | 6,718 | 6,033 |
| Selling, general and administrative | 36,330 | 30,935 | 25,672 | 11,994 | 8,534 | 7,479 |
| Operating income (loss) | (40,963) | (35,965) | (36,633) | (16,889) | (15,252) | (13,484) |
| Interest expense | 3,305 | 2,291 | 1,153 | 134 | 0 | — |
| Income tax expense (benefit) | 4 | 5 | 13 | 0 | 0 | 0 |
| Net income (loss) | (40,379) | (35,099) | 47,755 | (18,397) | (13,004) | (14,290) |
| Earnings per share, basic USD per share | — | (5.86) | 5.73 | (1.29) | (0.50) | (0.34) |
| Earnings per share, diluted USD per share | — | (5.86) | 5.72 | (1.29) | — | — |
| Weighted average shares, basic thousands of shares | — | 5,993 | 7,385 | 14,264 | 25,846 | 42,411 |
| Weighted average shares, diluted thousands of shares | — | 5,993 | 7,407 | 14,264 | — | — |
- † Share count changed about 3x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (TLPH's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 27,274 | 12,663 | 15,275 | 5,721 | 8,863 | 5,894 |
| Short-term investments | 15,612 | 38,967 | 495 | 3,660 | 0 | 14,487 |
| Accounts receivable | 635 | 160 | 309 | — | — | — |
| Inventory | 1,626 | 1,111 | 1,178 | — | — | — |
| Prepaid and other current assets | 1,683 | 2,588 | 2,309 | 2,175 | 554 | 519 |
| Total current assets | 46,830 | 55,489 | 24,566 | 11,556 | 9,417 | 20,900 |
| Property and equipment, net | 15,659 | 15,928 | 10,261 | — | — | — |
| Right-of-use asset | 3,150 | 4,302 | 3,595 | — | — | — |
| Total assets | 66,295 | 77,893 | 47,487 | 20,395 | 18,236 | 29,719 |
| Accounts payable | 2,737 | 2,121 | 2,040 | 1,336 | 670 | 544 |
| Accrued liabilities | 4,890 | 6,524 | 4,266 | 2,445 | 1,254 | 2,615 |
| Current portion of long-term debt | 8,735 | 8,796 | 5,763 | 0 | — | — |
| Total current liabilities | 17,635 | 18,509 | 13,770 | 4,512 | 2,647 | 3,809 |
| Long-term debt | 13,140 | 5,007 | 0 | — | — | — |
| Lease liability, non-current | 2,606 | 3,750 | 2,959 | — | — | — |
| Total liabilities | 122,045 | 113,786 | 25,673 | 6,290 | 10,235 | 12,684 |
| Accumulated deficit | (438,485) | (473,584) | (425,829) | (444,226) | (457,230) | (471,520) |
| Total stockholders' equity | (55,750) | (35,893) | 21,814 | 14,105 | 8,001 | 17,035 |
| Total liabilities and equity | 66,295 | 77,893 | 47,487 | 20,395 | 18,236 | 29,719 |
| Common shares outstanding (cover page) thousands of shares | 118,948 | 146,949 | 10,918 | 16,969 | 17,098 | 50,050 |
- † Share count changed about 3x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (TLPH's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (40,379) | (35,099) | 47,755 | (18,397) | (13,004) | (14,290) |
| Stock-based compensation | 4,424 | 4,609 | 2,889 | 1,729 | 989 | 699 |
| Depreciation and amortization | 1,853 | 1,973 | 1,647 | 311 | 0 | — |
| Net cash from operating activities | (38,505) | (30,002) | (28,331) | (17,492) | (12,683) | (11,364) |
| Purchases of property and equipment | 1,855 | 1,827 | 364 | 100 | 0 | — |
| Net cash from investing activities | 34,139 | (26,123) | 36,450 | (528) | 3,781 | (14,345) |
| Proceeds from issuing common stock | 21,337 | 44,716 | — | — | — | — |
| Proceeds from long-term debt | 0 | — | — | — | — | — |
| Repayments of long-term debt | 4,667 | 8,833 | 8,433 | 5,416 | 0 | — |
| Net cash from financing activities | 16,956 | 41,514 | (507) | 3,466 | 12,044 | 22,740 |
| Net change in cash | 12,590 | (14,611) | 7,612 | (14,554) | 3,142 | (2,969) |
- † Share count changed about 3x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Talphera | 742 | not reported | (3,924)* | 51.9M | 4.4 quarters | 10-QJun 30, 2026 |
| Biovie | 8,977 | not reported | (4,122)* | 7.5M | 2.2 quarters | 10-KJun 30, 2026 |
| Processa Pharmaceuticals | 196 | not reported | (1,996)* | 2.8M | 0.1 quarters | 10-QJun 30, 2026 |
| GT Biopharma | 4,960 | not reported | (4,260)* | 45.1M | 1.2 quarters | 10-QJun 30, 2026 |
| Orgenesis | 78 | 301* | (2,098)* | 9.8M | 0.0 quarters | 10-KDec 31, 2024 |
| TherapeuticsMD | 9,189 | not reported | not reported | 11.6M | — | 10-QJun 30, 2026 |
| Oncotelic Therapeutics | 186 | 250 | (92)* | 457.5M | 2.0 quarters | 10-QJun 30, 2026 |
| VivoSim Labs | 1,670 | 18 | (3,213) | 14.9M | 0.5 quarters | 10-QJun 30, 2026 |
| Genprex | 15,154 | not reported | (5,139)* | 819,709 | 2.9 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.